Literature DB >> 9295176

Concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism compared to Parkinson's disease patients.

H Tohgi1, T Abe, M Saheki, K Yamazaki, T Murata.   

Abstract

The concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism (VP) was compared to that in patients with Parkinson's disease (PD) and controls. Compared to the controls, the concentration of tyrosine was significantly higher, and the concentration of L-dopa and 3-O-methyldopa (3-OMD) was significantly lower in both VP and PD patients. The balance between the 3-OMD/L-dopa and dopamine (DA)/L-dopa ratios was changed in favor of 3-OMD/L-dopa in both VP patients and PD patients suggesting the preservation of a compensatory mechanism. All these changes were less marked in VP patients than in PD patients. A remarkable finding was that in contrast to PD patients the concentration of DA and norepinephrine (NE) was significantly higher in VP patients than in the controls. The decrease in the concentration of 5-hydroxytryptamine (5-HT) was significantly greater in VP patients than in PD patients. In PD patients, the concentration of DA, NE, and 5-HT showed significant correlation with the severity of motor symptoms. In VP patients, the concentration of 5-HT alone showed significant correlation with the severity of motor symptoms and cognitive dysfunction. These findings suggest that VP patients may have similar disturbances in the DA synthesis pathway as PD patients, but differ from PD patients in that the concentrations of DA and NE are elevated and the decrease in the 5-HT concentration is greater in VP patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9295176     DOI: 10.1007/BF01277662

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  24 in total

1.  Cerebrospinal fluid dopamine, norepinephrine, and epinephrine concentrations in Parkinson's disease correlated with clinical symptoms.

Authors:  H Tohgi; T Abe; S Takahashi; M Ueno; Y Nozaki
Journal:  Adv Neurol       Date:  1990

2.  Brain energy metabolism and catecholaminergic activity in hypoxia, hypercapnia and ischemia.

Authors:  B K Siesjö
Journal:  J Neural Transm Suppl       Date:  1978

3.  Increase in extracellular dopamine in the striatum during cerebral ischemia: a study utilizing cerebral microdialysis.

Authors:  A Slivka; T S Brannan; J Weinberger; P J Knott; G Cohen
Journal:  J Neurochem       Date:  1988-06       Impact factor: 5.372

4.  Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa.

Authors:  J D Parkes; C D Marsden; J E Rees; G Curzon; B D Kantamaneni; R Knill-Jones; A Akbar; S Das; M Kataria
Journal:  Q J Med       Date:  1974-01

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

6.  Concentrations of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type.

Authors:  H Tohgi; M Ueno; T Abe; S Takahashi; Y Nozaki
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1992

7.  [Distribution of 5-hydroxytryptamine (serotonin) in the human brain and its behavior in patients with Parkinson's syndrome].

Authors:  H BERNHEIMER; W BIRKMAYER; O HORNYKIEWICZ
Journal:  Klin Wochenschr       Date:  1961-10-15

8.  Concentrations of tyrosine, L-dihydroxyphenylalanine, dopamine, and 3-O-methyldopa in the cerebrospinal fluid of Parkinson's disease.

Authors:  H Tohgi; T Abe; S Takahashi; Y Nozaki; T Kikuchi
Journal:  Neurosci Lett       Date:  1991-06-24       Impact factor: 3.046

9.  Indoleamine concentrations in cerebrospinal fluid from patients with Alzheimer type and Binswanger type dementias before and after administration of citalopram, a synthetic serotonin uptake inhibitor.

Authors:  H Tohgi; T Abe; S Takahashi; M Saheki; M Kimura
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1995

10.  Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease.

Authors:  B Scatton; F Javoy-Agid; L Rouquier; B Dubois; Y Agid
Journal:  Brain Res       Date:  1983-09-26       Impact factor: 3.252

View more
  11 in total

1.  Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.

Authors:  Megan K Herbert; H Bea Kuiperij; Bastiaan R Bloem; Marcel M Verbeek
Journal:  J Neurol       Date:  2013-12       Impact factor: 4.849

2.  The effect of L-DOPA on Cryptococcus neoformans growth and gene expression.

Authors:  Helene C Eisenman; Siu-Kei Chow; Kenneth K Tsé; Erin E McClelland; Arturo Casadevall
Journal:  Virulence       Date:  2011-07-01       Impact factor: 5.882

Review 3.  Normal and pathological gait: what we learn from Parkinson's disease.

Authors:  David Grabli; Carine Karachi; Marie-Laure Welter; Brian Lau; Etienne C Hirsch; Marie Vidailhet; Chantal François
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-06-29       Impact factor: 10.154

4.  Methamphetamine Enhances Cryptococcus neoformans Melanization, Antifungal Resistance, and Pathogenesis in a Murine Model of Drug Administration and Systemic Infection.

Authors:  Victor H Erives; Melissa E Munzen; Daniel Zamith-Miranda; Hazael Hernandez; Swetha Manepalli; Long N Nguyen; Mohamed F Hamed; Joshua D Nosanchuk; Luis R Martinez
Journal:  Infect Immun       Date:  2022-03-31       Impact factor: 3.609

5.  Association between the levels of biogenic amines and superoxide anion production in brain regions of rats after subchronic exposure to TCDD.

Authors:  James P Byers; Karilane Masters; Jeffrey G Sarver; Ezdihar A Hassoun
Journal:  Toxicology       Date:  2006-09-29       Impact factor: 4.221

6.  Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons.

Authors:  Eugene V Mosharov; Kristin E Larsen; Ellen Kanter; Kester A Phillips; Krystal Wilson; Yvonne Schmitz; David E Krantz; Kazuto Kobayashi; Robert H Edwards; David Sulzer
Journal:  Neuron       Date:  2009-04-30       Impact factor: 17.173

7.  Noradrenaline and Parkinson's disease.

Authors:  Claire Delaville; Philippe De Deurwaerdère; Abdelhamid Benazzouz
Journal:  Front Syst Neurosci       Date:  2011-05-18

Review 8.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

9.  Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.

Authors:  Satoru Morimoto; Masaki Takao; Hiroyuki Hatsuta; Yasushi Nishina; Tadashi Komiya; Renpei Sengoku; Yuta Nakano; Akiko Uchino; Hiroyuki Sumikura; Yuko Saito; Kazutomi Kanemaru; Shigeo Murayama
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240

Review 10.  Development of early diagnosis of Parkinson's disease: Illusion or reality?

Authors:  Michael Ugrumov
Journal:  CNS Neurosci Ther       Date:  2020-06-29       Impact factor: 7.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.